Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPulmonologyAetna airway clearance coverage & prior auth | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0067

    Chest Physiotherapy and Airway Clearance Devices

    Customize your policy alerts

    Sign up for Aetna Policy 0067 alerts

    Get alerted when Policy 0067 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs medical necessity and coverage of chest physiotherapy and airway clearance devices (DME) for Aetna members, including indications, investigational devices, and applicable billing codes; affects providers prescribing or supplying these services and equipment.

    Policy Summary
    PayerAetna
    PolicyChest Physiotherapy and Airway Clearance Devices
    Policy CodePolicy 0067
    Change TypeNo material change
    Effective DateOct 23, 1995
    Last ReviewMar 17, 2023
    Next Review DateJan 11, 2024
    Key ActionObtain prior authorization and clinical documentation when requesting durable airway clearance equipment and ensure documentation shows indication and prior treatments tried.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multipledevice categories
    severalbilling code groups
    explicit listinvestigational devices
    specifiedHFCWO covered
    limitedevidence level
    03/17/2023last review

    Coverage Criteria for Chest Physiotherapy and Airway Clearance Devices

    Chest physiotherapy (therapist-delivered)

    Covered when specific conditions and context are met:

    Respiratory therapist CPT: Home chest physiotherapy is medically necessary upon initial prescription to stabilize the member and to train family members or caregivers to administer chest physiotherapy; chest physiotherapy is medically necessary when the member's pulmonary condition is unstable.

    Chest physiotherapy by a respiratory therapist is not considered medically necessary for persons whose pulmonary condition is stable, as chest physiotherapy can be competently administered at home by a family member or caregiver.

    Covered airway clearance DME and indications

    Airway clearance devices (DME) are covered when ALL of the following apply for the specified device classes:

    Oscillating devices: Airway oscillating devices (e.g., Flutter and Acapella) are medically necessary for cystic fibrosis (CF), chronic bronchitis, bronchiectasis, immotile cilia syndrome (primary ciliary dyskinesia) and asthma.
    Policy Summary
    PayerAetna
    PolicyChest Physiotherapy and Airway Clearance Devices
    Policy CodePolicy 0067
    Change TypeNo material change
    Effective DateOct 23, 1995
    Last ReviewMar 17, 2023
    Next Review DateJan 11, 2024
    Key ActionObtain prior authorization and clinical documentation when requesting durable airway clearance equipment and ensure documentation shows indication and prior treatments tried.
    SourceLink
    On This Page
    Coverage Criteria for Chest Physiotherapy and Airway Clearance DevicesBilling Codes and Coding GuidanceProvider Requirements, Prior Authorization & DocumentationBackground and PurposeDevice and Therapy DefinitionsPolicy History and Review Dates
    Mechanical percussors (e.g., Fluid Flo, Frequencer, VibraLung) are medically necessary for CF, chronic bronchitis, bronchiectasis, immotile cilia syndrome, and asthma.
    PEP mask: Positive expiratory pressure (PEP) masks are medically necessary for CF, chronic bronchitis, immotile cilia syndrome, asthma, and chronic obstructive pulmonary disease (COPD).
    HFCWO: High-frequency chest compression systems are medically necessary in lieu of chest physiotherapy when there is well-documented failure of standard treatments to adequately mobilize retained secretions and the member has one of the listed indications (bronchiectasis confirmed by CT with daily productive cough for ≥6 continuous months or >2 exacerbations/year requiring antibiotics; cystic fibrosis; immotile cilia syndrome; one of the enumerated neuromuscular diagnoses causing significant impairment of chest wall/diaphragmatic movement; or lung transplant recipients within the first 6 months post-operatively who are unable to tolerate standard chest physiotherapy).bronchiectasis: daily productive cough ≥6 months OR >2 exacerbations/year requiring antibiotics

    List of qualifying neuromuscular diagnoses is enumerated in policy (see policy text).

    Mechanical in-exsufflation: Mechanical insufflation-exsufflation devices are medically necessary for persons with neuromuscular disease causing significant impairment of chest wall and/or diaphragmatic movement for whom standard treatments (e.g., chest percussion and postural drainage) have not been successful in adequately mobilizing retained secretions.

    Examples of neuromuscular diagnoses include amyotrophic lateral sclerosis, congenital myopathies, inclusion body myositis, muscular dystrophy, myasthenia gravis, poliomyelitis, progressive bulbar palsy, spinal muscular atrophy, and high spinal cord injury with quadriplegia.

    Evidence summaries and situational considerations

    Summary of clinical evidence and contexts where devices may be considered

    HFCWO in cystic fibrosis: Randomized evidence does not support HFCWO as the primary form of airway clearance in CF compared with PEP; in the McIlwaine et al. randomized trial PEP had fewer pulmonary exacerbations (mean 1.14 vs 2.0) and longer time to first exacerbation

    Trial enrolled 107 subjects across 12 centers; results favored PEP over HFCWO for pulmonary exacerbations.

    HFCWO in infants/toddlers with recalcitrant atelectasis: Retrospective case series in infants and toddlers reported HFCWO was well tolerated and may be effective for recalcitrant atelectasis when combined with nebulized hypertonic saline; randomized trials are needed.

    Study included 23 patients (26 admissions); recommended further randomized study.

    IPV and other adjunctive therapies: Evidence for IPV is scarce and mixed; small studies and guideline reviews note insufficient high-quality data to recommend routine use.

    IPV evidence described as limited; routine use not supported without specific justification.

    Oscillating PEP/PEP: PEP devices have randomized data showing benefits versus conventional physiotherapy in some CF pediatric studies; Flutter/Acapella are widely used oscillating PEP devices with comparable performance characteristics.

    PEP trials showed improvements in some lung function and exacerbation outcomes compared with other techniques.

    Mechanical insufflation-exsufflation: Physiologic studies and small clinical trials report increased peak cough flows with MI-E in neuromuscular weakness; randomized evidence demonstrating improved morbidity or mortality is limited or lacking.

    Consensus reports support physiologic benefit but call out lack of morbidity/mortality data.

    MI-E / Cough augmentation

    Summary of clinical findings and contexts where devices were studied

    Mechanical insufflation-exsufflation (MI-E): MI-E alternates positive and negative airway pressure to simulate cough and assist secretion clearance; studies are small but have shown physiologic increases in peak cough flows, higher extubation success in one trial (82.9% vs 52.5%), reduced duration of mechanical ventilation in one trial, and greater airway mucus clearance in an ICU randomized study.

    Overall evidence quality rated low/very low with limited sample sizes and risk of bias; adverse events reported but few serious events.

    Other modalities (CHFO, nHFOV, HFNC, HFCWO)

    Findings from studies of other airway clearance or respiratory support modalities

    Continuous high-frequency oscillation (CHFO): Retrospective pediatric cohort of CHFO (MetaNeb) in mechanically ventilated children (59 subjects, 528 treatments) reported decreased peak inspiratory pressure, stable hemodynamics, and one clinically insignificant pneumothorax; authors call for prospective studies.

    Feasibility/safety data are preliminary and not definitive for efficacy.

    nHFOV in neonates: Small randomized trials comparing nasal high-frequency oscillation (nHFOV) with NCPAP in preterm neonates showed shorter duration of non-invasive support and, in some studies, reduced need for intubation or IVH; sample sizes were limited and larger trials recommended.

    Trials reported mixed but promising physiologic/clinical signals; routine adoption requires further evidence.

    High-flow nasal cannula (HFNC): Systematic reviews in critically ill patients show HFNC provides physiologic advantages but is not clearly superior to NIV or standard oxygen for invasive ventilation incidence or ICU mortality; indications and escalation criteria remain to be defined.

    Evidence heterogeneous across patient populations; further study needed for definitive guidance.

    HFCWO in mechanically ventilated/ICU patients: Randomized/observational studies in intubated patients with pneumonic respiratory failure indicate HFCWO can affect breathing pattern and oxygenation but results are exploratory with selection bias and small samples; HFCWO appeared safe though conventional chest physiotherapy sometimes maintained steadier conditions.

    Findings limited; larger studies needed to clarify clinical benefits.

    Evidence-based coverage considerations

    Evidence summary and implied coverage considerations based on clinical studies and device-specific findings

    OLE/Volara evidence: Prospective multi-center stage II cohort receiving OLE (Volara) reported reductions in postoperative pulmonary complications (PPCs), ventilator time, and hospital length of stay compared with a stage I historical cohort after adjustment; however the study was nonrandomized with baseline differences between stages and no differences were observed in ICU LOS, pneumonia, or mortality.p<0.05 for ventilator time and LOS; adjusted p<0.01 for PPC reduction

    Lack of randomized data and potential confounding limit certainty; absence of demonstrated improvement in key longer-term outcomes may influence coverage decisions.

    MetaNeb/MetaNeb OLE evidence: Evidence for MetaNeb/OLE systems is limited to case reports, cohort data, and ongoing trials; while some studies suggest physiologic benefit, there is insufficient high-quality evidence of improved health outcomes outside specific high-risk postsurgical protocols.

    Clinical trials are ongoing; lack of robust outcomes data may justify prior authorization or investigational status for some indications.

    HFAO/IMT trial implications: A randomized sham-controlled trial of combined high-frequency airway oscillation plus inspiratory muscle training in COPD showed no difference in the primary dyspnea outcome versus sham, though maximal inspiratory pressure improved; this suggests limited evidence to support routine coverage for dyspnea improvement alone in COPD.no statistical difference in primary outcome (CRQ-D), p=0.24

    Consider conservative/stepwise approaches (e.g., respiratory muscle training, PEP) before device coverage for dyspnea in COPD.

    Simeox BDD evidence implications: Pilot cohort data (n=21) for the Simeox bronchial drainage device showed altered sputum properties and increased diaphragm mobility but no change in spirometric parameters; evidence is preliminary and underpowered for patient-centered outcomes.n=21

    Insufficient evidence for routine coverage; further trials required.

    HFCWO safety/efficacy considerations in ventilated patients: Randomized/observational data in ventilated patients indicate HFCWO appears safe but efficacy signals are mixed and studies are limited by bias and small samples; these factors should inform cautious coverage decisions and documentation requirements.

    Recommend prior authorization and documentation of prior therapies and indication when considering high-cost modalities.

    Requests for high-frequency chest compression systems (HFCWO) when the member does not meet the policy's specified medical necessity criteria (for example, diagnoses such as alpha-1 antitrypsin deficiency, anoxic brain injury, cerebral palsy, childhood atelectasis, interstitial lung disease, scoliosis, Zellweger syndrome, and other listed conditions) may be considered experimental/investigational due to insufficient evidence of effectiveness and are subject to denial. The policy explicitly lists HFCWO for "other indications in members who do not meet medical necessity criteria" for which effectiveness has not been established.

    Randomized evidence in cystic fibrosis does not support HFCWO as the primary airway clearance modality compared with PEP mask therapy; a multicenter randomized trial reported fewer pulmonary exacerbations and longer time to first exacerbation with PEP than with HFCWO, and the authors concluded the results did not support HFCWO as primary therapy in CF. Similarly, intrapulmonary percussive ventilation (IPV) and other adjunctive therapies have limited and mixed evidence and are not supported as routine primary treatments without specific justification.

    No explicit coverage exclusions are stated in this portion of the document segment beyond the investigational/insufficient-evidence listings; the policy's exclusions and investigational device statements are provided elsewhere in the bulletin.

    The Volara System (OLE) and related MetaNeb/OLE-type devices lack sufficient evidence of improved health outcomes outside populations studied (for example, high‑risk postsurgical cohorts or research protocols). Use of these systems for indications without supporting outcomes data may be considered investigational.

    The policy's reference lists do not themselves specify coverage exclusions; they serve to document the literature cited in the bulletin rather than to define coverage determinations.

    Clinical Policy Bulletins are developed to assist in administering plan benefits and do not constitute offers of coverage or medical advice. These documents provide a general, partial description of plan benefits and do not replace program-specific contract language; treating providers remain responsible for medical decisions.

    Chest physiotherapy provided by a respiratory therapist is considered medically necessary for initial prescription and when the member's pulmonary condition is unstable. However, the policy specifies that respiratory therapist–delivered chest physiotherapy is not considered medically necessary for persons with a stable pulmonary condition because competent chest physiotherapy can be administered at home by a family member or caregiver.

    Routine or automatic use of intrapulmonary percussive ventilation (IPV) and similar adjunctive therapies in hospitalized or ventilated patients is not supported by sufficient scientific evidence; guideline panels have considered IPV but did not recommend it because of inadequate data, so routine coverage without specific justification is not supported.

    While physiologic and small clinical studies report improvements in cough mechanics and peak cough flows with some nonpharmacologic protussive therapies, the document notes that clinical studies demonstrating improvements in patient morbidity and mortality are generally lacking, limiting conclusions about the impact of many device‑based airway clearance interventions on major health outcomes.

    A randomized, double‑blind, sham‑controlled trial of combined high‑frequency airway oscillation with inspiratory muscle training in COPD did not show superiority over sham for the primary dyspnea outcome (CRQ‑D), indicating no demonstrated dyspnea benefit in that trial.

    Portions of the bulletin labeled as references contain citation listings only and serve as bibliographic support for the policy; they do not by themselves state clinical positions, coverage criteria, or medical necessity determinations.

    There are no explicit 'not medically necessary' statements contained in the referenced administrative/additional‑information chunks; the Additional Information section reiterates that the Clinical Policy Bulletin is informational and not a substitute for specific plan contract terms.

    Billing Codes and Coding Guidance

    Home Chest Physiotherapy CPT codesCPTCovered
    94667Manipulation chest wall, such as cupping, percussing and vibration to facilitate lung function; initial demonstration and/or evaluation or subsequent.
    94668Manipulation chest wall, such as cupping, percussing and vibration to facilitate lung function; initial demonstration and/or evaluation or subsequent.
    94669Mechanical chest wall oscillation to facilitate lung function, per session.
    97124Therapeutic procedure, one or more areas, each 15 minutes; massage, including effleurage, petrissage and/or tapotement (stroking, compression, percussion).
    Home Chest Physiotherapy HCPCS codesHCPCSCovered
    G0237Therapeutic procedures to increase strength or endurance of respiratory muscles, face-to-face, one-on-one, each 15 minutes (includes monitoring).
    G0238Therapeutic procedures to improve respiratory function, other than described by G0237, one-on-one, face-to-face, per 15 minutes (including monitoring).
    Flutter / Acapella device HCPCSHCPCSCovered
    S8185Flutter device.
    Mechanical percussors and PEP HCPCSHCPCSCovered
    E0480Percussor, electric or pneumatic, home model.
    E0484Oscillatory positive expiratory pressure device, non-electric, any type, each.
    High-frequency chest compression systems HCPCSHCPCSCovered
    E0483High frequency chest wall oscillation air-pulse generator system, (includes hoses and vest), each.
    A7025High frequency chest wall oscillation system vest, replacement for use with patient owned equipment, each.
    A7026High frequency chest wall oscillation system hose, replacement for use with patient owned equipment, each.
    Mechanical insufflation-exsufflation HCPCSHCPCSCovered
    E0482Cough stimulating device, alternating positive and negative airway pressure.
    A7020Interface for cough stimulating device, includes all components, replacement only.
    IPV HCPCSHCPCSNot Covered
    E0481Intrapulmonary percussive ventilation system and related accessories.
    ICD-10 codes covered when criteria metICD-10
    E84.0 - E84.9Cystic fibrosis.
    J47.0 - J47.9Bronchiectasis.
    J41.0 - J42Chronic bronchitis.
    J45.20 - J45.998Asthma.
    G12.20 - G12.29Motor neuron disease.
    G70.00 - G73.7Diseases of myoneural junction and muscle.
    G82.20 - G82.54Paraplegia and quadriplegia.
    Z94.2Lung transplant status.
    ICD-10 codes not covered for indications listed (not all-inclusive)ICD-10Not Covered
    E71.510Zellweger syndrome.
    F84.2Rett's syndrome.
    G25.82Stiff-Man Syndrome.
    J96.00 - J96.02Acute respiratory failure.
    J44.0 - J44.9Chronic obstructive pulmonary disease.
    Covered CPT Codesmixed
    No codes listed
    Coding referencedmixed
    none listedNo CPT/HCPCS/ICD codes are provided in this document segment.
    Device regulatory / 510(k)mixed
    K121170FDA 510(k) Premarket Notification (RespIn11 Model Powered Precursory)
    Covered CPT Codesmixed
    No codes listed
    Bronchiectasis clinical threshold
    Bronchiectasis symptom durationDaily productive cough for at least 6 continuous months
    Bronchiectasis exacerbation frequencyMore than 2 exacerbations per year requiring antibiotic therapy
    Diagnostic requirementBronchiectasis must be confirmed by CT scan
    ALS trial FVC inclusion
    Study inclusion FVC thresholdForced vital capacity (FVC) greater than or equal to 40% predicted
    Population describedPatients with probable or definite amyotrophic lateral sclerosis (ALS)
    Study duration context12-week exploratory randomized controlled trial
    OLE study sample size (stages I+II)
    Combined stages I+II sample size419 subjects
    Study designProspective multi-center comparison of stage II (OLE treatment) vs stage I historical/control cohort
    Primary reported outcomeReduction in postoperative pulmonary complications from 22.9% to 15.8% (adjusted p < 0.01)

    Provider Requirements, Prior Authorization & Documentation

    Prior Authorization

    Prior authorization required for durable airway‑clearance DME

    Prior authorization is required for durable airway clearance equipment (HFCWO systems, mechanical percussors, PEP devices, Flutter/Acapella, mechanical insufflation-exsufflation) and associated HCPCS/CPT codes; coverage is contingent on meeting the policy's clinical criteria.

    • Affected HCPCS/CPT codes include E0483, A7025, A7026, E0480, E0484, S8185, E0482, A7020 when selection criteria are met.
    Prior Authorization

    Recommend prior authorization for low‑evidence devices

    Devices and therapies with limited or mixed evidence (for example, HFCWO for some indications, IPV, mechanical insufflation‑exsufflation) may require prior authorization with documentation of clinical indication, prior therapies tried, and clinical rationale.

    • Policy notes lack of high‑level evidence for IPV and mixed/limited data for HFCWO outside CF.
    • Documentation should justify use given limited supporting trials and guideline statements.
    Prior Authorization

    No specific PA rules specified in this segment

    The document segment focuses on clinical evidence and device effectiveness and does not specify concrete prior authorization rules or programmatic PA procedures within these chunks.

    • Clinical content emphasizes efficacy/safety; billing or explicit PA directives are not provided here.
    Prior Authorization

    PA may be required for OLE/MetaNeb given limited evidence

    Prior authorization may be required when requesting Oscillation & Lung Expansion (OLE) systems such as Volara or MetaNeb because evidence demonstrating improved health outcomes is limited; requests should include clinical indication and supporting trial or risk‑factor data.

    • Volara/OLE evidence is limited and Huynh et al reported nonrandomized cohort comparisons; stage II OLE subjects were older with higher ASA but showed adjusted PPC reduction—documentation of patient risk factors and procedure type is relevant.
    Note

    Prior authorization not addressed in reference lists

    The reference lists and citation sections do not contain prior authorization rules or authorization requirements for providers.

    • References section supplies citations only and does not provide PA directives.
    Note

    Policy history does not specify PA requirements

    Policy history and administrative notes are provided but do not specify concrete prior authorization requirements or list affected billing codes in these administrative chunks.

    • Policy history shows last review and effective dates but contains no PA instructions.
    Step Therapy

    Try simpler/manual therapies before HFCWO for non‑CF indications

    For non‑CF indications, the policy indicates considering simpler or less expensive devices (e.g., Flutter, Acapella) or manual chest physiotherapy before approving HFCWO; HFCWO may be considered where manual therapy is unavailable or has failed.

    • Authors note absence of adequate studies comparing HFCWO to less expensive devices (Flutter/Acapella) and recommend considering alternatives.
    • HFCWO can be used in place of manual CPT when manual therapy is unavailable.
    Step Therapy

    Step through PEP/Flutter/Acapella before HFCWO

    When applicable, established airway‑clearance methods such as PEP (including Flutter/Acapella) should be attempted prior to higher‑cost modalities like HFCWO, supported by randomized evidence favoring PEP over HFCWO in CF.

    • McIlwaine et al (2013) randomized CF patients and found fewer pulmonary exacerbations with PEP versus HFCWO.
    Note

    No explicit step‑therapy algorithm provided

    The authors state that long‑term comparative data are lacking; explicit step‑therapy protocols are not specified in this document and further research is needed to evaluate relative success of airway‑clearance methods.

    • Policy text notes the need for long‑term comparisons and appropriate outcome measures before defining step therapy.
    Step Therapy

    Conservative first‑line approach suggested before device therapy

    Randomized trial evidence (e.g., HFAO + IMT vs sham in COPD) found no difference in primary dyspnea outcome, supporting a conservative, stepwise approach (e.g., respiratory muscle training or simpler therapies) before device therapy.

    • Daynes et al (2022) observed no statistical difference in CRQ‑D between HFAO and sham, suggesting conservative first‑line options may be reasonable.
    Note

    Step therapy requirements not discussed in references

    Reference entries in this portion do not discuss step‑therapy programmatic requirements or impose prior sequencing of therapies.

    • References supply background literature but not coverage sequencing rules.
    Note

    No step‑therapy rules specified in policy history

    The administrative and policy‑history chunks do not specify any step‑therapy requirements or mandated trial sequences for airway clearance devices.

    • Policy history and additional information emphasize that CPBs do not substitute for program contract language.
    Documentation Required

    Document clinical indication and prior treatments to justify DME

    Documentation submitted for device coverage must demonstrate the specific clinical indication (e.g., cystic fibrosis, bronchiectasis confirmed by CT with daily productive cough ≥6 months or >2 antibiotic‑requiring exacerbations/year, listed neuromuscular diagnoses, lung transplant within 6 months intolerant of CPT) and prior failure of standard treatments when applicable.

    • Policy enumerates qualifying conditions and broniectasis symptom/exacerbation thresholds for HFCWO coverage.
    Documentation Required

    Pediatric HFCWO requires radiographic and treatment‑failure documentation

    For pediatric or infant use of HFCWO to treat recalcitrant atelectasis, documentation should include radiographic evidence of atelectasis not responding to mucolytic therapy and conventional chest physiotherapy, device settings used, and tolerability.

    • Retrospective series reported radiographic confirmation and prior failure of mucolytic therapy and CPT; described tolerated device settings (e.g., 8 Hz × 10 min then 10 Hz × 10 min at pressure 15).
    Documentation Required

    Include trial characteristics and adverse‑event monitoring in supporting documentation

    Based on the evidence summaries, providers should include trial characteristics (study population, interventions, outcomes) and any adverse events or monitoring when documenting device use, as these factors were assessed in systematic reviews and primary studies.

    • Cochrane‑style reviews assessed RCTs and nonrandomized studies and reported risks of bias and harms; analogous documentation is expected in clinical practice.
    Documentation Required

    Provide OLE/Volara supporting trial‑style documentation (demographics, ASA, procedure type)

    For OLE/Volara requests, provide supporting documentation analogous to published studies (patient demographics, ASA score, procedure type, and baseline PPC risk) to justify use in high‑risk postsurgical patients.

    • Huynh et al reported adjusted analyses including age, ASA score, and operation time when assessing OLE impact on postoperative pulmonary complications.
    Note

    References do not specify provider documentation requirements

    The references section does not itself provide concrete provider documentation checklists or authorization forms; it is a bibliography of supporting literature.

    • Reference lists are for evidence support and do not replace required clinical documentation for authorization.
    Note

    Providers retain responsibility for treatment decisions despite CPB guidance

    Providers remain responsible for treatment decisions; the Clinical Policy Bulletin is intended to assist benefit administration and does not substitute for medical judgment or program‑specific contract rules.

    • Additional Information notes CPBs do not constitute offers of coverage or medical advice.
    Denial Risk

    Denial risk for devices listed as experimental/investigational

    Requests for devices or interventions listed as experimental/investigational (for example, IPV, Volara OLE, Simeox, and HFCWO when used for indications not meeting medical‑necessity criteria) are subject to denial.

    • Policy explicitly lists IPV, Volara OLE, Simeox, and HFCWO for non‑qualifying indications as experimental/investigational and not covered.
    Denial Risk

    Evidence gaps create coverage/denial risk

    Use of devices with insufficient evidence (for example, IPV or HFCWO as primary therapy in CF) or interventions not supported by randomized data may result in noncoverage or denial.

    • McIlwaine et al (2013) found PEP superior to HFCWO as primary therapy in CF; IPV is noted as lacking sufficient evidence and was considered but not recommended by guideline panels.
    Note

    No additional provider actions provided in this segment

    The document does not supply additional provider‑action content in this segment beyond the items already summarized.

    Denial Risk

    Volara (OLE) lack of evidence may lead to denial

    Lack of evidence supporting effectiveness of the Volara System in improving patient‑centered outcomes may trigger medical‑necessity denials for coverage of that device unless clear supporting clinical justification is provided.

    • Volara System OLE is described as lacking evidence to support improved health outcomes.
    Note

    No authorization or denial rules in reference sections

    The reference sections in these chunks do not state authorization requirements or specific denial triggers for providers.

    • Reference lists are cited for evidence and do not include PA or denial procedural content.
    Note

    No explicit denial triggers listed in these administrative chunks

    These document chunks do not list explicit denial triggers; denials are tied to devices or uses designated as experimental/investigational or lacking sufficient evidence.

    • Administrative material and additional information do not enumerate denial triggers beyond policy statements.

    Background and Purpose

    Chest physiotherapy and airway clearance techniques are intended to mobilize and remove pulmonary secretions to reduce airway obstruction, prevent or treat atelectasis, and decrease the risk of infection. Standard manual chest physiotherapy typically includes percussion, vibration, postural drainage and assisted coughing and is often delivered 1–3 times daily; device‑based therapies aim to permit independent use or substitute for manual therapy in select indications.

    Device and Therapy Definitions

    High-frequency chest wall oscillation (HFCWO)
    DefinitionHigh-frequency chest wall oscillation (HFCWO) is an inflatable vest connected to an air-pulse generator that provides external oscillatory compression of the chest to mobilize secretions
    Common trade names/examplesThe Vest, SmartVest, ThAIRapy Vest, ABI Vest, AffloVest, Respin11
    Intended useUsed in lieu of manual chest physiotherapy when standard treatments fail to mobilize retained secretions
    Mechanical insufflation-exsufflation
    DefinitionMechanical insufflation-exsufflation alternates positive and negative airway pressure to simulate a cough and assist secretion clearance
    HCPCS codeE0482 = Cough stimulating device, alternating positive and negative airway pressure
    Also known asCoughAssist, In-Exsufflator
    Flutter (oscillatory PEP device)
    DefinitionFlutter is a handheld oscillatory positive expiratory pressure device with a rolling ball that produces oscillations during exhalation to loosen mucus
    Device characteristicsPipe-like device with mouthpiece and stainless steel ball in a conical chamber
    Regulatory statusFlutter device has FDA 510(k) status
    PEP (Positive Expiratory Pressure)
    DefinitionPositive Expiratory Pressure (PEP) is a mask or mouthpiece valve that increases expiratory resistance to generate positive airway pressure during exhalation to aid secretion clearance
    Clinical evidenceA 1-year randomized trial in children with CF showed PEP improved pulmonary function vs conventional physiotherapy
    ExamplesResistex PEP Mask, TheraPep Valve, PARI PEP Mask
    IPV (Intrapulmonary Percussive Ventilator)
    DefinitionIntrapulmonary Percussive Ventilator (IPV) delivers pressurized gas minibursts (100–225 cycles/min) to provide percussion and aerosol delivery to the respiratory tract
    Intended functionProvides continuous monitored positive pressure application and percussion throughout the respiratory cycle with adjustable parameters
    Regulatory notePercussionaire IPV has FDA 510(k) status but evidence for effectiveness is scarce
    Mechanical insufflation-exsufflation (CoughAssist)
    Alternative labelCoughAssist (Mechanical insufflation-exsufflation)
    Function summaryDelivers positive pressure to inflate the lungs followed by negative pressure to assist cough and clear secretions
    Typical indicationsUsed in neuromuscular disease with impaired cough when standard therapies fail
    Frequencer
    DefinitionFrequencer is an electro-acoustical transducer device producing adjustable acoustic waves (20–100 Hz) applied externally to the chest to induce resonance and loosen mucus
    ComponentsControl unit and transducer (Power Head) placed on the chest; frequency and volume adjusted to create resonance
    Targeted patientsMay be appropriate for infants, elderly, agitated, immobilized, obese, and post-surgical patients
    MI-E (mechanical insufflation-exsufflation)
    ShorthandMI-E = Mechanical Insufflation-Exsufflation
    FunctionTechnique to increase inhaled volume prior to cough and apply negative airway pressure to augment cough flows
    Clinical contextAdvocated for patients with neuromuscular disease causing cough inefficiency
    CHFO (Continuous High-Frequency Oscillation / MetaNeb)
    DefinitionContinuous High-Frequency Oscillation (CHFO) (e.g., MetaNeb) creates oscillatory pressure gradients to facilitate secretion removal and may be combined with lung expansion therapies
    Intended useFacilitate secretion removal and treat atelectasis, often used in mechanically ventilated pediatric patients or as part of OLE devices
    Safety/feasibilityRetrospective pediatric cohort reported decreased peak inspiratory pressure and low rate of minor pneumothorax (2%)
    nHFOV (nasal high-frequency oscillation ventilation)
    DefinitionnHFOV (nasal high-frequency oscillation ventilation) is a non-invasive ventilation mode delivering high-frequency oscillatory airflow via the nares, considered for preterm neonates with RDS
    Clinical findingsRCTs report shorter duration of non-invasive support and reduced need for intubation in some trials but sample sizes are small
    PopulationPreterm neonates (e.g., 28–34 weeks gestational age) with respiratory distress syndrome
    HFNC (High-flow nasal cannula)
    DefinitionHigh-flow nasal cannula (HFNC) delivers heated, humidified high-flow oxygen up to about 60 L/min via nasal cannula, providing some PEEP and dead-space washout
    Physiologic advantagesReduces anatomical dead space, provides low-level PEEP, maintains constant FiO2, and improves humidification
    Evidence summaryMostly neonatal data; for adults evidence is uneven and definitive indications/criteria for escalation are unresolved
    HFCWO (definition, redundant entry)
    DefinitionHigh-frequency chest wall oscillation (HFCWO) is an inflatable vest connected to an air-pulse generator providing external oscillatory chest compression to mobilize secretions
    Use-caseCan be used in place of manual chest physiotherapy when manual CPT is unavailable or has failed
    ExamplesThe Vest, ThAIRapy Vest, SmartVest, ABI Vest, AffloVest
    OLE (Oscillation & Lung Expansion) therapy device
    DefinitionOLE (Oscillation & Lung Expansion) therapy device combines continuous positive expiratory pressure (CPEP), continuous high-frequency oscillation (CHFO) pulses, and nebulized medication to dislodge mucus and expand lungs
    Example systemVolara System (OLE)
    Evidence noteLack of robust evidence for improved health outcomes overall; one prospective multi-center study (combined n=419) reported reduced postoperative pulmonary complications in stage II
    HFAO (High-Frequency Airway Oscillation)
    DefinitionHFAO (High-Frequency Airway Oscillation) delivers oscillatory airflow intended to aid secretion clearance and has been studied combined with inspiratory muscle training
    Clinical trial resultRandomized sham-controlled trial in COPD found no difference in primary dyspnea outcome (CRQ-D) between HFAO+IMT and sham
    Measured benefitSmall improvement in maximal inspiratory pressure observed in HFAO group
    Simeox Bronchial Drainage Device (BDD)
    DefinitionSimeox Bronchial Drainage Device (BDD) disseminates a vibratory pneumatic signal during exhalation to mobilize distal mucus in cystic fibrosis patients
    Pilot studySingle-center prospective cohort (n=21) showed improved diaphragm mobility and altered sputum properties but no change in spirometric PFTs
    Evidence statusPilot/early evidence; further study required for patient-centered outcomes
    HFCWO — reference cluster
    Definition clusterHigh-frequency chest wall oscillation (HFCWO) — inflatable vest + air-pulse generator; multiple randomized and observational studies cited in references
    Representative referencesSee reference list entries for The Vest and related trials (chunks 72, 16, 19)
    Clinical noteUsed in CF and other indications when manual CPT unavailable or has failed; randomized data in CF do not support HFCWO as superior to PEP
    IPV — reference cluster
    Definition clusterIPV — delivers pressurized gas minibursts (100–225 cycles/min) for percussion and aerosol delivery; device has 510(k) status
    Evidence summaryScientific data are scarce and mixed; small pilot studies show equivalence to standard therapy but larger trials needed
    Reference locationsSee IPV reference list entries (chunks 79–80)
    Oscillating PEP devices (Flutter/Acapella) — references
    Definition clusterOscillating PEP devices (Flutter, Acapella) — handheld devices combining PEP with oscillation to facilitate mucus clearance
    Comparative notesAcapella and Flutter have similar performance characteristics; Acapella is not gravity-dependent
    ReferencesMultiple comparative and clinical trials cited (chunks 82–83)
    PEP mask/valve — reference cluster
    Definition clusterPEP mask/valve — mask or mouthpiece providing expiratory back-pressure to improve ventilation and mucus clearance
    Clinical evidencePEP has RCT evidence (including a 1-year trial in children with CF) showing pulmonary function benefits
    Representative devicesResistex PEP Mask, TheraPep Valve, PARI PEP Mask
    Mechanical insufflation-exsufflation — reference cluster
    Definition clusterMechanical insufflation-exsufflation — device-assisted cough augmentation delivering positive then negative airway pressure to simulate cough
    Evidence summaryPhysiologic studies show increased peak cough flows in neuromuscular weakness; clinical outcome studies are limited and of low quality
    ReferencesMultiple systematic reviews and clinical studies cited (chunks 89–91, 92–93)
    In-Exsufflation and related airway clearance therapies — extended references
    Definition and scopeIn-Exsufflation and related airway clearance therapies encompass mechanical insufflation-exsufflation (MI-E), oscillatory devices, PEP, IPV, CHFO, HFNC, and bronchial drainage devices discussed in the literature
    Evidence noteLiterature includes systematic reviews, small RCTs, case series, and physiologic studies; clinical outcome evidence (morbidity/mortality) is generally limited
    Reference breadthExtensive reference lists for in-exsufflation and related therapies are provided (see chunks 89–97)

    Policy History and Review Dates

    Policy history and administrative review information are provided in the bulletin's Additional Information section; these administrative notes reinforce that the Clinical Policy Bulletin is intended to guide benefit administration but is not a contract and does not replace provider clinical judgment.